Hoth Therapeutics, Inc.
Hoth Therapeutics is dedicated to developing innovative, impactful, and ground-breaking treatments to improve patient quality of life. They focus on early-stage pharmaceutical research and development, collaborating with scientists, clinicians, and key opinion leaders to seek out and investigate promising medications. Their mission is driven by a patient-centric approach, aiming to create breakthroughs and diversify treatment options across various therapeutic areas including oncology, neurology, inflammatory diseases, dermatology, and medical devices.
Industries
Nr. of Employees
small (1-50)
Products
HT-001
A topical treatment aimed at reducing skin toxicities associated with EGFR inhibitor cancer therapy.
BioLexa
A topical lotion for treating eczema flares by targeting S. aureus colonization contributing to skin barrier dysfunction.
HT-KIT Injection
Targets proto-oncogene c-KIT for treating mast cell derived cancers and has received Orphan Designation.
HT-ALZ
An oral soluble film for Alzheimer’s disease treatment, leveraging existing safety data for expedited development.
HT-TBI
An injectable treatment for traumatic brain injury and ischemic stroke, focusing on emergency and non-clinic use.
HT-004
An Antisense oligonucleotide for treating IgE-mediated allergies and asthma, targeting FcεRIβ via alternative splicing.
HT-001
A topical treatment aimed at reducing skin toxicities associated with EGFR inhibitor cancer therapy.
BioLexa
A topical lotion for treating eczema flares by targeting S. aureus colonization contributing to skin barrier dysfunction.
HT-KIT Injection
Targets proto-oncogene c-KIT for treating mast cell derived cancers and has received Orphan Designation.
HT-ALZ
An oral soluble film for Alzheimer’s disease treatment, leveraging existing safety data for expedited development.
HT-TBI
An injectable treatment for traumatic brain injury and ischemic stroke, focusing on emergency and non-clinic use.
HT-004
An Antisense oligonucleotide for treating IgE-mediated allergies and asthma, targeting FcεRIβ via alternative splicing.
Services
Drug development partnerships
Collaborative arrangements with academic groups, clinicians, and contract organizations to advance early-stage therapeutic candidates from bench to pre-clinical and early clinical stages.
Clinical development and patient program support
Support for clinical trial activities and patient-facing programs including expanded access and compassionate use pathways.
Translational research and pre-clinical study execution
Design and execution of pre-clinical studies including behavioral assessments in rodent models and application of in vivo analytical methods for protein kinetics.
Drug development partnerships
Collaborative arrangements with academic groups, clinicians, and contract organizations to advance early-stage therapeutic candidates from bench to pre-clinical and early clinical stages.
Clinical development and patient program support
Support for clinical trial activities and patient-facing programs including expanded access and compassionate use pathways.
Translational research and pre-clinical study execution
Design and execution of pre-clinical studies including behavioral assessments in rodent models and application of in vivo analytical methods for protein kinetics.
Expertise Areas
- Early-stage drug development
- Pre-clinical pharmacology and animal models
- Translational research
- Neurodegenerative disease research
Key Technologies
- Micro-immunoelectrode (MIE) technology for in vivo protein measurement
- In vivo microdialysis
- Rodent behavioral assay platforms
- Electrochemical aerosol pathogen detection sensors